Background
Phase III open-label RCT, N=410 patients with locally advanced or metastatic biliary tract cancer — intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary cancer — with no prior systemic therapy. Conducted across UK centers (National Cancer Research Network). Enrolled 2005–2009.
Interventions and follow up
Arm A: Gemcitabine 1000 mg/m² + cisplatin 25 mg/m² days 1 and 8 q3wk × up to 8 cycles
Arm B: Gemcitabine 1000 mg/m² days 1, 8, 15 q4wk × up to 8 cycles
Primary endpoint: Overall survival (OS)
Median follow-up: 8.2 months
Arm B: Gemcitabine 1000 mg/m² days 1, 8, 15 q4wk × up to 8 cycles
Primary endpoint: Overall survival (OS)
Median follow-up: 8.2 months
Results
OS: 11.7 vs 8.1 months, HR 0.64 (95% CI 0.52–0.80), P<.001
PFS: 8.0 vs 5.0 months, HR 0.63 (95% CI 0.51–0.77), P<.001
ORR: 26.1% vs 15.2%, P=.005
PFS: 8.0 vs 5.0 months, HR 0.63 (95% CI 0.51–0.77), P<.001
ORR: 26.1% vs 15.2%, P=.005
Adverse events
Hematologic: Grade ≥3 neutropenia 25% vs 17% (Arm A vs B).
Overall: Grade 3–4 AEs 69% vs 65%; combination did not significantly worsen quality of life versus gemcitabine alone. Cisplatin-associated nephrotoxicity manageable with dose caps.
Overall: Grade 3–4 AEs 69% vs 65%; combination did not significantly worsen quality of life versus gemcitabine alone. Cisplatin-associated nephrotoxicity manageable with dose caps.
Conclusions
Gemcitabine plus cisplatin significantly improved OS and PFS compared to gemcitabine alone (OS 11.7 vs 8.1 months, HR 0.64, P<.001) in advanced biliary tract cancer, establishing gem+cis as the global standard first-line regimen for this disease for over a decade.
Key Limitations
Median OS of 11.7 months in the combination arm reflects the poor overall prognosis of BTC — absolute benefit is modest (~3.6 months). Trial included biologically heterogeneous populations: ampullary cancers alongside intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer. Conducted before modern molecular profiling — FGFR2 fusions, IDH1/2 mutations, HER2 amplification, and BRAF alterations now guide targeted therapy in molecularly selected subsets, and the trial does not inform these decisions. Open-label design. Gemcitabine monotherapy is not a contemporary comparator — subsequent immunotherapy trials (TOPAZ-1, KEYNOTE-966) built on gem+cis as the backbone rather than comparing against it directly.
Clinical Context
ABC-02 established gemcitabine+cisplatin as the global standard first-line regimen for advanced biliary tract cancer from 2010 onward. This standard persisted for over a decade until TOPAZ-1 (durvalumab+gem/cis, FDA-approved 2022) and KEYNOTE-966 (pembrolizumab+gem/cis, FDA-approved 2023) added immunotherapy to the backbone. Current first-line standard in advanced BTC is durvalumab+gem/cis or pembrolizumab+gem/cis. Gemcitabine+cisplatin remains the chemotherapy backbone in all modern first-line regimens, making ABC-02 the foundational chemotherapy reference trial in biliary cancer.
References